Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Exelixis’ cabozantinib received Fast Track designation by US FDA for RCC treatment
The US Food & Drug Administration (FDA) has granted Fast Track designation to Exelixis, Inc's cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC). Cabozantinib is the Exelixis' lead compound . Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer.
- Read more about Dr. Reddy’s Laboratories and its subsidiary filed three NDAs for psoriasis, rosacea and migraine
Dr. Reddy's Laboratories and its subsidiary, Promius Pharma™, LLC announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.S. Food and Drug Administration (US FDA).
- Read more about India examines WTO option over EU drug suspension order
India is examining whether to take up with World Trade Organisation (WTO) the European Union's (EU) suspension order for sale of about 700 generic drugs which were approved based on clinical trials by pharma major GVK Biosciences.
- Read more about Pharma sector to soon showcase new drugs: Vardhan
The Indian pharmaceutical sector would soon be showcasing new drugs for malaria, osteoporosis and diabetes, Union Minister for Science and Technology Harsh Vardhan said. These drugs are currently undergoing clinical trials, he said.

[adsense:336x280:8701650588]
- Read more about Sun Pharma, Israel university ink pact to develop anti-cancer drugs
Sun Pharmaceutical Industries has inked a pact with Israel's Technion university to develop anti-cancer drugs. The subsidiaries of the Mumbai-based drug firm and Technion - Israel Institute of Technology have entered into an exclusive worldwide research and license agreement, Sun Pharma said in a statement.
- Read more about Gum disease treatment is linked with preventing Heart Disease
A new study from the Forsyth Institute is helping to shed more light on the important connection between the mouth and heart. According to research recently published online by the American Heart Association, scientists at Forsyth and Boston University have demonstrated that using an oral topical remedy to reduce inflammation associated with periodontitis, more commonly known as gum disease, also results in the prevention of vascular inflammation and can lower the risk of heart attack.
- Read more about Genetically modified Salmonella may treat Cancer
Genetically modified Salmonella can kill cancer cells, suggests new research published in mBio, an American Society for Microbiology. one particular strain of salmonella found to be most effective at killing cancer cells and shrinking tumors, and also not toxic.
- Read more about US FDA approved Aurobindo anesthesia supplement drug product
Aurobindo Pharma has received the final approval from the US Food and Drug Administration to manufacture and market Atracurium Besylate injection in single and multi-dose vials in the US market.
- Read more about US FDA approved indication for Ethicon’s EVARREST Fibrin Sealant Patch
Ethicon, a part of J&J, received expanded FDA indication for its EVARREST Fibrin Sealant Patch to be used to help control bleeding during adult liver surgeries. The device is bioabsorbable and contains human thrombin and fibinogen proteins that participate in clot formation. It retains its strength and stickiness while it’s still around. EVARREST is a novel convergence of biologics and medical device that rapidly and reliably stops problematic bleeding during surgery on the first attempt in indicated patients. EVARREST is a fibrin sealant patch indicated for use with manual compression as an adjunct to hemostasis . The unmatched mechanism of action behind EVARREST drives rapid and durable clot formation. The technology is comprised of a flexible composite patch, which contains embedded human biologics (human thrombin and fibrinogen), which are proteins involved in the natural clotting process.
- Read more about Ferring Pharma's new room temperature stable formulation of Pabal approved through EU
Ferring Pharmaceuticals, a research-driven, specialty biopharmaceutical group active in global markets, announced that EU has approved its new room-temperature-stable formulation of Pabal (carbetocin) for intravenous (IV) administration.